Engineered RNA Modification Recognition

Abstract Alida Biosciences Inc is developing a commercial platform for the analysis of the epitranscriptome, which is the totality of chemical modifications applied naturally to RNA to regulate possibly all aspects of RNA biology: transcription (mods are installed co-transcriptionally), translation, transcript lifetime, trafficking, alternative splicing, RNA folding, RNA–protein interactions, and more. The field of epitranscriptomics has seen rapid growth, motivated by the significance of this biology and the emerging opportunities to use RNA modifications as diagnostic biomarkers and to intervene in epitranscriptomic pathways as a promising novel paradigm in drug development, especially in cancer chemotherapy. Alida’s platform technology will make epitranscriptomics more accessible by offering a user-friendly workflow, integrated process controls, and cloud-based data handling and bioinformatics. In this SBIR grant, we seek to develop engineered RNA modification binding agents for integration into our platform. The enhanced properties of the novel agents will be optimized specifically for our platform to maximize sensitivity and selectivity, which is especially significant for high-value clinical samples in which only sub-nanogram quantities of RNA are likely to be available: needle biopsies, FFPE samples, and others.

抽象的 Alida Biosciences Inc正在开发一个商业平台，用于分析同志，这是 大量化学修饰自然应用于RNA，以调节RNA生物学的所有方面： 转录（mod是共同安装的），翻译，笔录寿命，贩运，替代方案 剪接，RNA折叠，RNA - 蛋白质相互作用等等。表面参考组学领域已经迅速增长， 受到这种生物学的意义以及新兴的RNA修改的机会的动机 诊断生物标志物并干预同志途径，作为一种有希望的新型药物范式 发育，特别是在癌症化疗中。 Alida的平台技术将使关注分组学更多 通过提供用户友好的工作流，集成过程控件以及基于云的数据处理以及 生物信息学。在SBIR赠款中，我们寻求开发设计的RNA修饰绑定剂 集成到我们的平台中。新型药物的增强特性将专门针对我们 平台以最大化灵敏度和选择性，这对于高价值临床样本特别重要 可能只有次图量的RNA可用：针头活检，FFPE样品和 其他的。